Ident. | Authors (with country if any) | Title |
---|
000198 |
Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne] | Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study |
000206 |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
000285 |
Christopher G. Goetz [États-Unis] ; Eugene Laska [États-Unis] ; Christine Hicking [Allemagne] ; Philippe Damier [France] ; Thomas Müller [Allemagne] ; John Nutt [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne] | Placebo influences on dyskinesia in Parkinson's disease |
000308 |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
000317 |
Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne] | Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial |
000318 |
Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France] | Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study |
000424 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |